KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) EBITDA (2016 - 2026)

Boston Scientific's EBITDA history spans 18 years, with the latest figure at $1.1 billion for Q1 2026.

  • On a quarterly basis, EBITDA rose 19.54% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.8 billion, a 33.13% increase, with the full-year FY2025 number at $3.6 billion, up 38.8% from a year prior.
  • EBITDA hit $1.1 billion in Q1 2026 for Boston Scientific, up from $825.0 million in the prior quarter.
  • Over the last five years, EBITDA for BSX hit a ceiling of $1.1 billion in Q1 2026 and a floor of $358.0 million in Q3 2022.
  • Historically, EBITDA has averaged $665.2 million across 5 years, with a median of $675.0 million in 2024.
  • The widest YoY moves for EBITDA: up 123.33% in 2022, down 7.49% in 2022.
  • Tracing BSX's EBITDA over 5 years: stood at $402.0 million in 2022, then soared by 45.27% to $584.0 million in 2023, then grew by 15.58% to $675.0 million in 2024, then increased by 22.22% to $825.0 million in 2025, then soared by 33.45% to $1.1 billion in 2026.
  • Business Quant data shows EBITDA for BSX at $1.1 billion in Q1 2026, $825.0 million in Q4 2025, and $1.0 billion in Q3 2025.